Your browser is no longer supported. Please, upgrade your browser.
Settings
CEMI Chembio Diagnostics, Inc. daily Stock Chart
CEMI [NASD]
Chembio Diagnostics, Inc.
Index- P/E- EPS (ttm)-0.93 Insider Own0.20% Shs Outstand17.20M Perf Week-7.87%
Market Cap169.49M Forward P/E3.71 EPS next Y2.43 Insider Trans0.00% Shs Float16.82M Perf Month-26.37%
Income-15.90M PEG- EPS next Q0.06 Inst Own41.40% Short Float5.69% Perf Quarter141.82%
Sales33.00M P/S5.14 EPS this Y-48.00% Inst Trans-3.29% Short Ratio0.73 Perf Half Y121.08%
Book/sh1.05 P/B8.59 EPS next Y109.38% ROA-30.80% Target Price- Perf Year34.43%
Cash/sh0.60 P/C15.13 EPS next 5Y25.00% ROE-66.10% 52W Range2.25 - 15.89 Perf YTD97.81%
Dividend- P/FCF- EPS past 5Y-46.60% ROI-30.50% 52W High-43.23% Beta2.31
Dividend %- Quick Ratio2.10 Sales past 5Y4.50% Gross Margin33.40% 52W Low300.89% ATR1.37
Employees295 Current Ratio3.50 Sales Q/Q-18.80% Oper. Margin-44.10% RSI (14)43.43 Volatility10.27% 11.64%
OptionableYes Debt/Eq1.01 EPS Q/Q-77.20% Profit Margin-48.00% Rel Volume0.63 Prev Close8.85
ShortableYes LT Debt/Eq0.99 EarningsMay 04 AMC Payout- Avg Volume1.31M Price9.02
Recom1.50 SMA20-18.69% SMA50-11.13% SMA20047.54% Volume826,110 Change1.92%
May-26-20Initiated Robert W. Baird Outperform $21
Mar-04-20Reiterated The Benchmark Company Speculative Buy $9 → $6
Mar-04-20Reiterated The Benchmark Company Speculative Buy $9 → $5
Dec-19-18Initiated Dougherty & Company Buy
Aug-11-16Reiterated The Benchmark Company Speculative Buy $10 → $9
Apr-18-16Reiterated The Benchmark Company Speculative Buy $6 → $8
Nov-04-15Initiated The Benchmark Company Speculative Buy $6
Sep-10-13Resumed The Benchmark Company Speculative Buy $7
Jun-02-20 08:00AM  
May-26-20 04:15PM  
May-25-20 06:40PM  
May-18-20 07:00AM  
May-11-20 10:20AM  
May-07-20 08:55AM  
May-06-20 04:01PM  
02:51PM  
May-05-20 04:13PM  
May-04-20 04:05PM  
04:04PM  
Apr-27-20 04:05PM  
Apr-22-20 04:40PM  
Apr-19-20 08:13AM  
Apr-17-20 10:23AM  
Apr-16-20 08:47AM  
07:57AM  
Apr-15-20 09:26AM  
Apr-10-20 09:54AM  
Apr-09-20 04:05PM  
Apr-08-20 08:00AM  
Apr-02-20 09:25AM  
Apr-01-20 07:38AM  
Mar-31-20 09:10PM  
Mar-20-20 08:30AM  
08:00AM  
Mar-15-20 08:47AM  
Mar-13-20 07:38PM  
07:52AM  
Mar-12-20 04:46PM  
04:07PM  
08:00AM  
Mar-11-20 04:10PM  
Mar-03-20 05:42PM  
08:30AM  
Feb-28-20 09:32AM  
Feb-12-20 07:45AM  
Jan-09-20 04:15PM  
04:05PM  
Jan-03-20 07:55AM  
Jan-02-20 04:05PM  
Dec-30-19 02:05PM  
Nov-27-19 04:22PM  
Nov-25-19 11:22PM  
04:30PM  
Nov-14-19 04:40PM  
Nov-12-19 06:43AM  
Nov-07-19 04:05PM  
04:03PM  
Nov-04-19 08:00AM  
Oct-24-19 08:00AM  
Oct-17-19 08:00AM  
Oct-13-19 09:34AM  
Sep-13-19 08:18AM  
Sep-04-19 08:00AM  
Aug-27-19 04:05PM  
Aug-15-19 12:05PM  
Aug-14-19 11:28AM  
Aug-06-19 04:05PM  
Jul-24-19 04:05PM  
08:00AM  
Jul-18-19 08:00AM  
Jul-15-19 01:43PM  
Jun-27-19 09:27AM  
May-07-19 08:00AM  
May-06-19 09:17AM  
May-01-19 04:05PM  
Apr-29-19 10:44AM  
Apr-22-19 05:11PM  
Apr-09-19 08:02AM  
Apr-08-19 12:48AM  
Apr-02-19 08:00AM  
Mar-18-19 10:00AM  
08:48AM  
Mar-11-19 02:26PM  
Mar-07-19 05:00PM  
04:02PM  
Feb-25-19 08:30AM  
Feb-19-19 06:17PM  
Feb-07-19 08:20AM  
Feb-06-19 07:30AM  
Jan-17-19 04:10PM  
Jan-07-19 07:00AM  
Jan-01-19 02:49PM  
Dec-06-18 08:00AM  
Nov-29-18 04:30PM  
Nov-19-18 05:00AM  
Nov-13-18 08:20AM  
Nov-09-18 11:14AM  
08:00AM  
Nov-08-18 04:18PM  
Nov-01-18 07:00AM  
Oct-31-18 04:05PM  
08:00AM  
Oct-25-18 08:00AM  
Oct-22-18 05:27PM  
04:38PM  
Oct-17-18 07:00AM  
01:00AM  
Oct-16-18 07:00AM  
Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. The company offers tests for HIV and Syphilis, and Zika virus. It also develops tests for malaria, Dengue virus, chikungunya virus, ebola, lassa, marburg, leptospirosis, Rickettsia typhi, Burkholderia pseudomallei, and Orientia tsutsugamushi. In addition, the company develops tests for a specific form of cancer, concussion, and bovine tuberculosis; and handheld optical analyzers for rapid diagnostic tests. It sells its products under the STAT-PAK, SURE CHECK, STAT VIEW, or DPP trademarks, as well as under the private labels of its marketing partners to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals, and retail establishments in the United States and internationally. The company has collaboration agreements with Concussion Science Group Division of Perseus Science Group LLC to develop a POC diagnostic test for traumatic brain injury; Foundation for Innovative New Diagnostics to develop a POC fever panel assay for life-threatening acute febrile illnesses; AstraZeneca to develop a POC test for eosinophilic respiratory disease; and Shire Human Genetic Therapies, Inc. to develop a novel POC diagnostic test. It also has a strategic partnership with LumiraDx Limited to develop point-of-care diagnostic tests for the detection of the COVID-19 virus, and IgM and IgG antibodies on the LumiraDx and Chembio DPP platforms. Chembio Diagnostics, Inc. was founded in 1985 and is headquartered in Hauppauge, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Potthoff John GaryDirectorNov 11Buy4.4410,00044,40037,772Nov 13 07:21 PM